Journal Logo

CARFILZOMIB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS FROM PHASE 3 ASPIRE AND ENDEAVOR

PS1387

Facon, T.1; Niesvizky, R.2; Weisel, K.3; Bringhen, S.4; Ho, P. J.5; Obreja, M.6; Yang, Z.6; Klippel, Z.6; Blaedel, J.6; Mezzi, K.6; Siegel, D.7

doi: 10.1097/01.HS9.0000563824.64379.80
Poster Session II: Myeloma and other monoclonal gammopathies - Clinica
Free

1Hôpital Claude Huriez, Lille, France

2Weill Cornell Medicine, New York, United States

3Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

4Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

5Royal Prince Alfred Hospital, Camperdown, Australia

6Amgen Inc, Thousand Oaks

7John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, United States

Back to Top | Article Outline

Background:

Carfilzomib (K)-based regimens improved progression-free survival (PFS) and overall survival (OS) in relapsed and refractory multiple myeloma (RRMM) patients (pts) in ASPIRE (K [27 mg/m2]-lenalidomide-dexamethasone [KRd] vs Rd) and ENDEAVOR (K [56 mg/m2]-dexamethasone [Kd56] vs bortezomib-dexamethasone [Vd]), regardless of age. Frailty scores have been developed based on age, comorbidities, and functional status (Palumbo Blood 2015;125:2068-74; Facon Blood 2015;126:4239).

Back to Top | Article Outline

Aims:

We assessed post-hoc pt outcomes by frailty status.

Back to Top | Article Outline

Methods:

PFS, OS, and safety were assessed by treatment arm and frailty score (based on age, medical history-derived Charlson Comorbidity Index, and ECOG performance status); frailty scores: 0 = fit, 1 = intermediate (int), and ≥2 = frail.

Back to Top | Article Outline

Results:

Pt frailty status was balanced between treatment arms in ASPIRE and ENDEAVOR. Median PFS and OS were longer with K-based regimens vs controls in ASPIRE and ENDEAVOR across frailty subgroups (Table). Rates of treatment-emergent adverse events are summarized in the Table.

Figure

Figure

Back to Top | Article Outline

Summary/Conclusion:

Kd56 and KRd consistently improved outcomes vs Vd and Rd, respectively, in all frailty subgroups as defined by the algorithm above. These findings support the favorable benefit-risk profile of KRd and Kd56 regardless of frailty score.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.